ESTRO Brachytherapy for Prostate Cancer 2018

Low Risk and favourable Intermediate Risk

5 studies - 4 studies describing outcome in patients treated with LDR +/- ADT - 1 study describing outcome in patients treated with LDR +/- EBRT +/- ADT

ADT used in 27-65% of patients ADT duration 3-6 mths

Most often: downside prostate volume before BT and in one study for IR features

• None of the studies showed any benefit from ADT to bPFS. • Effect on CSS not reported • Not associated with improved or detrimental OS